TECENTRIQ
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
Priority Review
TECENTRIQ by Roche is l1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Approved for following platinum-containing chemotherapy, metastatic hepatocellular carcinoma (hcc), metastatic melanoma [see ] and 2 more indications. First approved in 2016.
Drug data last refreshed 3d ago
Mechanism of Action
L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD L1 to the PD 1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell…
Indications (4)
Worked on TECENTRIQ at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.